← Back to Search

Alkylating Agent

Nivolumab for Multiple Myeloma

Phase 2

Waitlist Available

Research Sponsored by Andrew Yee, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing a new combination treatment for multiple myeloma that has relapsed or become resistant to other treatments.

Eligible Conditions

Multiple Myeloma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective Response Rate (ORR)

Secondary outcome measures

Progression Free Survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: Nivolumab and IxazomibExperimental Treatment4 Interventions

- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle. Oral: Ixazomib given weekly on days 1, 8, 15 Dexamethasone given weekly during cycle Infused: Nivolumab given once per cycle Cyclophosphamide given on days 1, 8, 15 during cycle

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nivolumab

FDA approved

Ixazomib

FDA approved

Dexamethasone

FDA approved

Cyclophosphamide

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Andrew Yee, MDLead Sponsor

1 Previous Clinical Trials

43 Total Patients Enrolled

1 Trials studying Multiple Myeloma

43 Patients Enrolled for Multiple Myeloma

Bristol-Myers SquibbIndustry Sponsor

2,638 Previous Clinical Trials

4,128,512 Total Patients Enrolled

87 Trials studying Multiple Myeloma

29,918 Patients Enrolled for Multiple Myeloma

Takeda Pharmaceuticals North America, Inc.Industry Sponsor

57 Previous Clinical Trials

8,961 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many test subjects are participating in this clinical research?

"This clinical trial is no longer enrolling candidates. It was initially posted on January 14th, 2020 and last updated May 14th 2021. However, those seeking trials related to multiple myeloma can find 807 active studies while 1987 experiments are currently recruiting for Ixazomib treatments."

Answered by AI

What potential risks accompany the utilization of Ixazomib?

"Ixazomib's safety has been partially substantiated due to the fact it is in phase 2, hence our team at Power assigned a rating of 2. However, no evidence exists yet that proves its efficacy."

Answered by AI

What medicinal purposes does Ixazomib typically serve?

"While primarily utilized to address malignant melanoma of skin, ixazomib is also employed as a remedy for leukemia, synovitis, ophthalmia and sympathetic diseases."

Answered by AI

Are there any additional investigations concerning the benefits of Ixazomib?

"Presently, 1987 trials for Ixazomib are underway worldwide with 350 of these studies in Phase 3. While Philadelphia, Pennsylvania is the primary hub where research is being conducted, 81150 locales across the globe have active investigations on this medication."

Answered by AI

Is access to this experiment currently available for participants?

"According to clinicaltrials.gov, this medical research is not currently recruiting patients. It was originally posted January 14th 2020 with the latest edits being made May 14th 2021. At present, there are 2794 other studies that are still enrolling participants into their trials."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Andrew Yee, MD 2020. "Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04119336.